OBJECTIVE: Few studies have investigated whether a diagnosis of @entity1279 ( @entity1279 ) confers additional risk of life-threatening behaviors such as self-harm and suicidal behavior in @entity4225 ( @entity4225 ). METHOD: @entity1 were 483 treatment-seeking @entity1 diagnosed with @entity4225 according to the Structured Clinical Interview for DSM-IV @entity1314 ( @entity915 -II; First, Gibbon, Spitzer, Williams, _ Benjamin, 1997; Diagnostic and Statistical Manual of @entity146 , 4th ed.; APA, 1994) and admitted to the Norwegian Network of Psychotherapeutic Day Hospitals between 1996 and 2009. Of these, 57 (11.8%) @entity1 met DSM-IV diagnostic criteria for @entity1279 according to the Mini-International Neuropsychiatric Interview (M.I.N.I.; Sheehan et al., 1998) and they were compared with @entity1 with @entity4225 and other @entity74 . RESULTS: We found that comorbid @entity1279 is uniquely and significantly associated with increased risk of suicidal behavior among @entity1 being treated for @entity4225 . Findings underscore the importance of routinely screening for @entity1279 among @entity1 seeking treatment for @entity4225 , as co-occurring @entity6426 appears to be a significant marker for immediate life-threatening behaviors in this already high-risk population, which is a significant public health issue. A significantly greater proportion of @entity1 with @entity4225 - @entity1279 reported suicidal ideation at intake (past 7 days), engaged in self-harm behavior during treatment, and attempted suicide during treatment. All bivariate associations remained significant in the logistic regression models after controlling for mood, @entity148 , and @entity734 . CONCLUSION: The presence of a concurrent diagnosis of @entity1279 among @entity1 with @entity4225 is significantly and uniquely associated with recent suicidal ideation, and self-harm behavior and suicide attempts during treatment after controlling for major classes of @entity146 . Co-occurring @entity1279 appears to represent a significant marker for immediate life-threatening behaviors in @entity1 seeking treatment for @entity4225 . Extra vigilance and careful monitoring of suicidal behavior during treatment is important for these individuals, and routine screening for @entity1279 is warranted. (PsycINFO Database Record

Self-harm and suicidal behavior in @entity4225 with and without XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'Participants'] @entity4225 :: ('MESH:D001883', 'Disease') :: ['borderline personality disorder', 'BPD'] @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorders', 'Mental Disorders'] @entity6426 :: ('MESH:D002032', 'Disease') :: ['bulimia'] @entity915 :: ('MESH:D053632', 'Disease') :: ['SCID'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety'] @entity74 :: ('MESH:D030342', 'Disease') :: ['Axis I disorders'] @entity1279 :: ('MESH:D052018', 'Disease') :: ['Bulimia nervosa', 'BN'] @entity1314 :: ('MESH:D010554', 'Disease') :: ['Axis II Personality Disorders'] @entity734 :: ('MESH:D019966', 'Disease') :: ['substance-related disorders']
@entity1279 :: (MESH:D052018,Disease) :: ['bulimia nervosa']
